Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Cited by (1,000)

Items 101–200 of 1,000

1. Contribution of oncoproteomics to cancer biomarker discovery
   William Chi Shing Cho · 2007 · Molecular Cancer
2. Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells
   Yanyuan Wu, Charles Ginther, Juri Kim, Nicole Mosher, SEYUNG S. CHUNG, Dennis J. Slamon, Jaydutt V. Vadgama · 2012 · Molecular Cancer Research
3. Current Perspectives on HER2 Testing: A Review of National Testing Guidelines
   Michael Bilous, Mitch Dowsett, Wedad M. Hanna, Jorma J Isola, Annette Lebeau, Aberlardo Moreno, Frederique Madeleine Penault-Llorca, Josef Rüschoff, Gorana Tomasic, Marc J. van de Vijver · 2003 · Modern Pathology
4. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification
   Javier Abel Menéndez, Luciano Vellón, Rámón Colomer, Ruth Lupu · 2005 · Annals of Oncology
5. Nuclear Targeting Dynamics of Gold Nanoclusters for Enhanced Therapy of HER2+ Breast Cancer
   Yuling Wang, Jiji Chen, Joseph Irudayaraj · 2011 · ACS Nano
6. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
   Wenle Xia, Catherine M. Gerard, Lei-Hua Liu, Nathalie Baudson, T. Ory, Neil L. Spector · 2005 · Oncogene
7. Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications
   Cynthia Osborne, P. Wilson, Debu Tripathy · 2004 · The Oncologist
8. Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2- Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
   Vicente Valero, John Forbes, Mark Daniel Pegram, Tadeusz Pieńkowski, Wolfgang EIERMANN, Gϋnter von Minckwitz, Henri Hubert Roche, Miguel Martín, John Paul Crown, John Robert Mackey et al. · 2010 · Journal of Clinical Oncology
9. Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab
   Alessandra Magnifico, Luisa Albano, Stefano Campaner, Domenico Delia, Fabio Castiglioni, Patrizia Gasparini, Gabriella Sozzi, Enrico Fontanella, Sylvie Ménard, Elda Tagliabue · 2009 · Clinical Cancer Research
10. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
    Nicole M. Davis, Melissa L. Sokolosky, Kristin M. Stadelman, Stephen Lee Abrams, Massimo Libra, Saverio Candido, Ferdinando Nicoletti, Jerry Polesel, Roberta Maestro, Antonino B. D’Assoro et al. · 2014 · Oncotarget
11. Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
    Filip Jankú, David J. Stewart, Razelle Kurzrock · 2010 · Nature Reviews Clinical Oncology
12. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
    Shivanni Kummar, Helen X. Chen, John Wright, Susan L. Holbeck, Myrtle Davis Millin, Joseph E. Tomaszewski, James Zweibel, Jerry M. Collins, James H. Doroshow · 2010 · Nature Reviews Drug Discovery
13. Targeted Molecular Therapy of GBM
    Paul S. Mischel, Timothy Francis Cloughesy · 2003 · Brain Pathology
14. Targeting Akt in cancer for precision therapy
    Hui Ming Hua, Hongying Zhang, Jingzhu Chen, Jiao Wang, Jieya Liu, Yangfu Jiang · 2021 · Journal of Hematology & Oncology
15. Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
    René Bruno, Carla B. Washington, Jianfeng Lü, Grazyna Liebérman, Ludger Banken, Pamela M. Klein · 2005 · Cancer Chemotherapy and Pharmacology
16. Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer
    Mariana Chávez‐MacGregor, Ning Zhang, Thomas A. Buchholz, Yufeng Zhang, Jiangong Niu, Linda S. Elting, Benjamin D. Smith, Gabriel N. Hortobágyi, Sharon Hermes Giordano · 2013 · Journal of Clinical Oncology
17. Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
    Xiaoping Huang, Li‐Zhi Gao, Shuiliang Wang, James L. McManaman, Ann D. Thor, Xiao-He Yang, Francisco J. Esteva, Bolin Liu · 2010 · Cancer Research
18. Lack of clinical efficacy of imatinib in metastatic melanoma
    Selma Ugurel, Ralf Hildenbrand, A Zimpfer, Paul Graf La Rosée, Peter Paschka, Antje Sucker, Petra Keikavoussi, Jürgen Christian Becker, Werner Rittgen, Andreas Hochhaus et al. · 2005 · British Journal of Cancer
19. Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
    Pasi Antero Janne, Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Thomas E. Stinchcombe, Lin Gu, Marzia Capelletti, Martin Joseph Edelman, Miguel Angel Villalona-Calero, Robert Arthur Kratzke et al. · 2012 · Journal of Clinical Oncology
20. Validation of Analytic Methods for Biomarkers Used in Drug Development
    Cindy H. Chau, Olivier Rixe, Howard L. McLeod, William Douglas Figg · 2008 · Clinical Cancer Research
21. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
    Claudio Vernieri, Monica Milano, Marta Brambilla, Alessia Mennitto, Claudia Maggi, Maria Silvia Cona, Michele Prisciandaro, Chiara Fabbroni, Luigi Celio, Gabriella Mariani et al. · 2019 · Critical Reviews in Oncology/Hematology
22. TrkA overexpression enhances growth and metastasis of breast cancer cells
    Chann H. Lagadec, Samuel Meignan, Éric Adriaenssens, Bénédicte Foveau, Elsa Vanhecke, Rodrigue Romon, Robert‐Alain Toillon, Bénédicte Oxombre, Hubert Hondermarck, Xuefen Le Bourhis · 2009 · Oncogene
23. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
    Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald Steven Falchook et al. · 2016 · Cancer Research
24. HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
    Suthinee Ithimakin, Kathleen C. Day, Fayaz Ahmad Malik, Qin Zen, Scott J. Dawsey, Tom F. Bersano-Begey, Ahmed A. Quraishi, Kathleen Woods Ignatoski, Stephanie D. Daignault, April Davis et al. · 2013 · Cancer Research
25. Androgen receptors frequently are expressed in breast carcinomas
    Farid Moinfar, Murat Ökcü, Oleksiy Tsybrovskyy, Peter Regitnig, Sigurd Lax, Wolfgang Weybora, Manfred Ratschek, Fattaneh A. Tavassoli, Helmut Denk · 2003 · Cancer
26. Clinical development of targeted and immune based anti-cancer therapies
    Nicole A. Seebacher, Alexandra E. Stacy, Georgia Porter, Angelica M. Merlot · 2019 · Journal of Experimental & Clinical Cancer Research
27. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
    Yu Kataoka, Toru Mukohara, Hiroyuki Shimada, Nagahiro Saijo, M. Hirai, Hironobu Minami · 2009 · Annals of Oncology
28. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
    Alberto Gallardo, Enrique Lerma, Daniel Escuín, Ariadna Tibau, Josefina Muñoz, Belen Ojeda, Agustí Barnadas, Encarna Adrover, Laura Sánchez-Tejada, Daniel Giner et al. · 2012 · British Journal of Cancer
29. Clinical Implications of the Cancer Genome
    Laura E. MacConaill, Levi A. Garraway · 2010 · Journal of Clinical Oncology
30. Targeting tumour-supportive cellular machineries in anticancer drug development
    Matthias Dobbelstein, Ute Martha Moll · 2014 · Nature Reviews Drug Discovery
31. Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
    Ritwik Ghosh, Archana Narasanna, Shizhen Emily Wang, Shuying Liu, Anindita Chakrabarty, Justin Micah Balko, Ana Maria Gonzalez-Angulo, Gordon Brent Mills, Elicia M. Penuel, John William Winslow et al. · 2011 · Cancer Research
32. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
    Jens Huober, Peter Andreas Fasching, Maged Sami Barsoum, Lubos B. Petruzelka, Diethelm R. Wallwiener, Christoph Thomssen, Toralf Reimer, Stefan Paepke, Hamdy A. Azim, Volker Ragosch et al. · 2011 · The Breast
33. Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer
    Jose M Baselga, Edith A. Perez, Tadeusz Pieńkowski, Richard H. Bell · 2006 · The Oncologist
34. Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
    Teemu T. Junttila, Kathryn L. Parsons, Christine Olsson, Yanmei Lu, Yan Xin, Julie Theriault, Lisa Crocker, Oliver Pabonan, Tomasz Baginski, Gloria Meng et al. · 2010 · Cancer Research
35. A role for microfluidic systems in precision medicine
    José María Ayuso, Marı́a Virumbrales-Muñoz, Joshua Michael Lang, David J. Beebe · 2022 · Nature Communications
36. Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
    Noel O. Dybdal, Grazyna Leiberman, Steven Anderson, Bryan K. McCune, Alex Bajamonde, Robert L. Cohen, ROBERT D. MASS, Corsee Sanders, Michael F. Press · 2005 · Breast Cancer Research and Treatment
37. Micro-NMR for Rapid Molecular Analysis of Human Tumor Samples
    Jered B. Haun, Cesar Martin Castro, Rui Wang, Vanessa M. Peterson, Brett S. Marinelli, Hakho Lee, Ralph Weissleder · 2011 · Science Translational Medicine
38. The Insulin-Like Growth Factor System in Cancer
    S. John Weroha, Paul Haluska · 2012 · Endocrinology and Metabolism Clinics of North America
39. Epithelial-Mesenchymal Transition and Breast Cancer
    Yanyuan Wu, Marianna Sarkissyan, Jaydutt V. Vadgama · 2016 · Journal of Clinical Medicine
40. Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
    Ernest Ramsay Camp, Justin M. Summy, Todd W. Bauer, Wenbiao Liu, Gary E. Gallick, Lee M. Ellis · 2005 · Clinical Cancer Research
41. Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
    Guanglei Zhuang, Dana M. Brantley‐Sieders, David Vaught, Jian Yu, Lu Xie, Sam Wells, Dowdy Jackson, Rebecca S. Muraoka-Cook, Carlos L. Arteaga, Jin Chen · 2009 · Cancer Research
42. Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
    Scott M. Knowles, Anna M. Wu · 2012 · Journal of Clinical Oncology
43. Future cancer research priorities in the USA: a Lancet Oncology Commission
    Elizabeth M. Jaffee, Chi Van Dang, David B. Agus, Brian Michael Alexander, Kenneth Carl Anderson, Alan Ashworth, Anna D. Barker, Roshan Bastani, Sangeeta N. Bhatia, Jeffrey A. Bluestone et al. · 2017 · The Lancet Oncology
44. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor
    Clodia Osipo, P Patel, Paola Rizzo, Anthony George Clementz, L Hao, Todd Eliot Golde, Lucio Miele · 2008 · Oncogene
45. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
    Mitra, Doyel, Brumlik, Michael J., Okamgba, Stella U., Zhu, Yun, Duplessis, Tamika T., Parvani, Jenny G., Lesko, Samuel M., Brogi, Edi, Jones, Frank E. · 2009 · Molecular Cancer Therapeutics
46. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004
    Monica M. Brown, Alex Tsodikov, Katrina R. Bauer, Carol A. Parise, Vincent Caggiano · 2008 · Cancer
47. Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
    Janneke F. Linnekamp, Xin Wang, Jan Paul Medema, Louis Vermeulen · 2015 · Cancer Research
48. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers
    Kristina W. Thiel, Luiza I. Hernandez, Justin P. Dassie, William H. Thiel, Xiuying Liu, Katie R. Stockdale, Alissa M. Rothman, Frank J. Hernández, James O McNamara, Paloma H. Giangrande · 2012 · Nucleic Acids Research
49. Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency
    Chien‐Hsing Lu, Shannon L. Wyszomierski, Ling‐Ming Tseng, Meng-Hong Sun, Keng‐Hsueh Lan, Christopher L. Neal, Gordon Brent Mills, Gabriel N. Hortobágyi, Francisco J. Esteva, Dihua Yu · 2007 · Clinical Cancer Research
50. Quality of Life in Thyroid Cancer is Similar to That of Other Cancers with Worse Survival
    Megan K. Applewhite, Benjamin Christopher James, Sharone P. Kaplan, Peter Angelos, Edwin L. Kaplan, Raymon H. Grogan, Briseis Aschebrook‐Kilfoy · 2015 · World Journal of Surgery
51. Role of Three-Dimensional Echocardiography in Breast Cancer: Comparison With Two-Dimensional Echocardiography, Multiple-Gated Acquisition Scans, and Cardiac Magnetic Resonance Imaging
    Jonathan R. Walker, Navdeep Bhullar, Nazanin Fallah‐Rad, Matthew Lytwyn, Mehrdad Golian, Tielan Fang, Arthur R. Summers, Pawan K. Singal, Ivan Barač, Iain D. Kirkpatrick et al. · 2010 · Journal of Clinical Oncology
52. Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer
    Ma, Cynthia X., Bose, Ron, Gao, Feng, Freedman, Rachel A., Telli, Melinda L., Kimmick, Gretchen, Winer, Eric, Naughton, Michael, Goetz, Matthew P., Russell, Christy et al. · 2017 · Clinical Cancer Research
53. Targeting the function of the HER2 oncogene in human cancer therapeutics
    Mark M. Moasser · 2007 · Oncogene
54. Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers
    Daniel Gray, Adrian M. Jubb, Deborah A. Hogue, Patrick Dowd, Noelyn M. Kljavin, Sothy Yi, Wei Bai, Gretchen D. Frantz, Zemin Zhang, Hartmut Koeppen et al. · 2005 · Cancer Research
55. The biology of breast carcinoma
    Judith Clancy Keen, Nancy E. Davidson · 2003 · Cancer
56. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma
    Hanning You, Wei Ding, Hien T. Dang, Yixing Jiang, Bart C. Rountree · 2011 · Hepatology
57. Emerging Targeted Therapies for Breast Cancer
    Ricardo H. Álvarez, Vicente Valero, Gabriel N. Hortobágyi · 2010 · Journal of Clinical Oncology
58. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection
    Marco Bruno Morelli, Chiara Bongiovanni, Silvia Da Pra, Carmen Miano, Francesca Sacchi, Mattia Lauriola, Gabriele D’Uva · 2022 · Frontiers in Cardiovascular Medicine
59. Current and Future Management of HER2-Positive Metastatic Breast Cancer
    Olga Martínez‐Sáez, Aleix Prat · 2021 · JCO Oncology Practice
60. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
    Ali M. Ziada, Al Baha Barqawi, L. Michael Glode, Marileila Varella‐Garcia, Frances Crighton, Susan Majeski, Mark Rosenblum, Madeleine A. Kane, Lin Chen, E. David Crawford · 2004 · The Prostate
61. Interlaboratory Comparison ofHER-2Oncogene Amplification as Detected by Chromogenic and Fluorescencein situHybridization
    Jorma J Isola, Minna Tanner, Amanda Forsyth, Timothy G. Cooke, Amanda D. Watters, John M.S. Bartlett · 2004 · Clinical Cancer Research
62. Mutational analysis of the <i>HER2</i> gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features
    Buttitta, Fiamma, Barassi, Fabio, Fresu, Giuseppina, Felicioni, Lara, Chella, Antonio, Paolizzi, Diego, Lattanzio, Giuseppe, Salvatore, Simona, Camplese, Pier P., Rosini, Sandra et al. · 2006 · International Journal of Cancer
63. Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
    Maria Luque-Cabal, Paula García‐Teijido, Yolanda Fernández-Pérez, Luisa Sánchez‐Lorenzo, Isabel Palacio Vázquez · 2016 · Clinical Medicine Insights Oncology
64. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
    Joan T. Garrett, Carlos L. Arteaga · 2011 · Cancer Biology & Therapy
65. Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
    Chantal Bernard-Marty, Fátima Cardoso, Martine J Piccart · 2004 · The Oncologist
66. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
    Aleix Prat, Jose M Baselga · 2008 · Nature Clinical Practice Oncology
67. Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
    Gabriel Tinoco, Sean Warsch, Stefan Glück, Kiran Kumar Venkata Raja Avancha, Alberto J. Montero · 2013 · Journal of Cancer
68. Immunotherapy: A Challenge of Breast Cancer Treatment
    Marilina García‐Aranda, Maximino Redondo · 2019 · Cancers
69. Identification of Subtypes in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome
    Johan Staaf, Markus Ringnér, Johan Vallon‐Christersson, Goran B Jönsson, Pär‐Ola Bendahl, Karolina Holm, Aðalgeir Arason, Haukur Gunnarsson, Cecilia Hegardt, Bjarni Agnar Agnarsson et al. · 2010 · Journal of Clinical Oncology
70. Current and Future Treatment Strategies for Rhabdomyosarcoma
    Celine Y. Chen, Heathcliff Dorado García, Monika Scheer, Anton George Henssen · 2019 · Frontiers in Oncology
71. HER-2/neu expression in primary and metastatic breast cancer
    Elyse E. Lower, Eleanor L. Glass, Robbin Blau, Stacy Harman · 2008 · Breast Cancer Research and Treatment
72. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
    Michael F. Press, Richard S. Finn, David Cameron, Angelo Di Leo, Charles E. Geyer, Ivonne E. Villalobos, Angela Santiago, Roberta Guzman, Armen Gasparyan, Yanling Ma et al. · 2008 · Clinical Cancer Research
73. Advances in the preclinical testing of cancer therapeutic hypotheses
    Caponigro, Giordano, Sellers, William R. · 2011 · Nature Reviews Drug Discovery
74. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
    Markus K. Muellner, Iris Z. Uras, Bianca V. Gapp, Claudia Kerzendorfer, Michal Šmída, Hannelore Lechtermann, Nils Craig-Mueller, Jacques Colinge, Gerhard Duernberger, Sebastian M. B. Nijman · 2011 · Nature Chemical Biology
75. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
    Gϋnter von Minckwitz, W. Jonat, Peter Andreas Fasching, Andreas du Bois, Ulrich Richard Kleeberg, Hans‐Joachim Lück, Erika Kettner, J. Hilfrich, Wolfgang EIERMANN, Julie Torode et al. · 2005 · Breast Cancer Research and Treatment
76. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging
    Heike Elisabeth Daldrup-Link, Reinhard Meier, Martina Rudelius, Guido Piontek, Morand Piert, Stephan Metz, Marcus Settles, Christoph Uherek, Winfried S. Wels, Jürgen Schlegel et al. · 2004 · European Radiology
77. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery
    Yutao Liu, Kai Li, Bin Liu, Si‐Shen Feng · 2010 · Biomaterials
78. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer
    Thomas M. Suter, Nancy Cook‐Bruns, Claire M. Barton · 2003 · The Breast
79. Expression patterns of potential therapeutic targets in prostate cancer
    Tobias Zellweger, Christoph Ninck, Michael Bloch, Martina Mirlacher, Pasi A. Koivisto, Heikki J. Helin, Michael Jörg Mihatsch, Thomas C. Gasser, Lukas Bubendorf · 2004 · International Journal of Cancer
80. EGFR, HER2 and VEGF Pathways
    Michael F. Press, Heinz‐Josef Lenz · 2007 · Drugs
81. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
    Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Kasper Pedersen, Neil A. O’Brien, Ioannis Roxanis, Ji‐Liang Li, Esther Bridge et al. · 2013 · Oncotarget
82. Prioritizing targets for precision cancer medicine
    Fabrice André, Elaine R. Mardis, Maximilian P Salm, Jean‐Charles Soria, Lillian L. Siu, Charles Swanton · 2014 · Annals of Oncology
83. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
    Hee Eun Lee, Kyoung Un Park, Seol Bong Yoo, Soo Kyung Nam, Do Joong Park, Hyung‐Ho Kim, Hye Seung Lee · 2012 · European Journal of Cancer
84. Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy
    Vishad Nabili, Jesse W. Tan, Sunita M. Bhuta, Joel A. Sercarz, Christian S. Head · 2007 · Head & Neck
85. Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
    John W. Park, Robert S. Kerbel, Gary J. Kelloff, J. Carl Barrett, Bruce Allan Chabner, David R. Parkinson, Jonathan C. Peck, Raymond W. Ruddon, Caroline C. Sigman, Dennis J. Slamon · 2004 · Clinical Cancer Research
86. Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
    Chia C. Portera, Janice Maria Walshe, Douglas R. Rosing, Neelima Denduluri, Arlene W. Berman, Ujala Vatas, Margarita Velarde, Catherine K. Chow, Seth M. Steinberg, Diana Nguyen et al. · 2008 · Clinical Cancer Research
87. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study
    Deepa Wadhwa, Nazanin Fallah‐Rad, Debjani Grenier, Marianne Krahn, Tielan Fang, Roien Ahmadie, Jonathan R. Walker, Danica Lister, Rakesh Christopher Arora, Ivan Barač et al. · 2008 · Breast Cancer Research and Treatment
88. Targeting Akt3 Signaling in Triple-Negative Breast Cancer
    Y. Rebecca Chin, Taku Yoshida, Andriy Marusyk, Andrew H. Beck, Kornélia Polyák, Alex Toker · 2013 · Cancer Research
89. The Exciting New Field of HER2-Low Breast Cancer Treatment
    Daniel Eiger, Elisa Agostinetto, Rita Saúde-Conde, Evandro de Azambuja · 2021 · Cancers
90. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    Francisco J. Esteva, Carol D Cheli, Herbert A. Fritsche, Monica Nancy Fornier, Dennis J. Slamon, Robert P. Thiel, Diana Lüftner, Farooq Ghani · 2005 · Breast Cancer Research
91. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
    Feng Xu, Alexander Sunderland, Yue Zhou, Richard David Schulick, Barish H. Edil, Yuwen Zhu · 2017 · Cancer Immunology Immunotherapy
92. Current approaches and future directions in the treatment of HER2-positive breast cancer
    Sara Alsterlind Hurvitz, Yufang Hu, Neil A. O’Brien, Richard S. Finn · 2012 · Cancer Treatment Reviews
93. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis
    Aadya Nagpal, Richard P. Redvers, Xiawei Ling, Scott Ayton, Miriam Fuentes, Elnaz Tavancheh, Irmina Diala, Alshad S. Lalani, Sherene Loi, Steven David et al. · 2019 · Breast Cancer Research
94. The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition
    Xiao‐Feng Le, Francois-Xavier Claret, Amy Lammayot, Ling Tian, Deepa M. Deshpande, Ruth LaPushin, Ana Maria Tari, Robert C. Bast · 2003 · Journal of Biological Chemistry
95. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
    Hans‐Joachim Stemmler, Steffen Kahlert, Wolfgang Siekiera, Michael Untch, Bernhard Heinrich, Volker Heinemann · 2005 · The Breast
96. Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells
    Yu Zhou, Daryl C. Drummond, Hao Zou, Mark E. Hayes, Gregory Paul Adams, Dmitri B. Kirpotin, James D. Marks · 2007 · Journal of Molecular Biology
97. Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management
    Valentina Guarneri, Simona Giovannelli, Guido Ficarra, Stefania Raffaella Bettelli, Antonino Maiorana, Federico Piacentini, Elena Barbieri, Maria Vittoria Dieci, Roberto D’Amico, Gordana Jovic et al. · 2008 · The Oncologist
98. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
    Filippo Montemurro, Serena Di Cosimo, Grazia Arpino · 2013 · Annals of Oncology
99. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
    Heini J. Lassus, Harri J. Sihto, Arto Leminen, Heikki Joensuu, Jorma J Isola, Nina N. Nupponen, Ralf C. Bützow · 2006 · Journal of Molecular Medicine
100. The use of RNA-based treatments in the field of cancer immunotherapy
     Mohammad Chehelgerdi, Matin Chehelgerdi · 2023 · Molecular Cancer